Skip to main content
UniHealth

Doctor search

Hayley Wheeler Leatham, MD

Dermatology · Stanford

NPI 1295197028

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Offices
3

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leatham’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A151279 · Current

Licensed to practise in California · since 2017 · expires 2027-04-30 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$248,161

Medicare paid this office $248,161 for 661 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)424$65,527$111
Biopsy of related skin growth, first growth258$28,016$90
Destruction of precancer skin growth, 1 growth357$21,349$47
Destruction of skin growth, 1-14 growths127$18,928$109
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm47$16,790$300
See all 19 services
Every Original Medicare service billed
Return visit (30+ min)424$65,527$111
Biopsy of related skin growth, first growth258$28,016$90
Destruction of precancer skin growth, 1 growth357$21,349$47
Destruction of skin growth, 1-14 growths127$18,928$109
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm47$16,790$300
Short return visit (20+ min)128$12,419$76
Destruction of precancer skin growth, 2-14 growths291$11,671$7
New patient visit (30+ min)122$10,251$84
Biopsy of related skin growth, each additional growth108$8,147$47
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)15$6,739None
Destruction of precancer skin growth, 15 or more growths26$5,410$164
Punch biopsy, first skin growth39$4,650$116
New patient visit (15+ min)63$3,942$63
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm22$3,324$138
Short return visit52$2,930$51
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm17$2,217$123
Injection into skin growth, 1-7 growths29$1,993$47
Application of light to destroy precancer skin growth13$1,963$151
Injection, triamcinolone acetonide, not otherwise specified, 10 mg29$49None

Procedures Medicare counted

Procedure volume Medicare published
Melanoma (skin cancer) excision46More than 86% of doctors who do this
Removal of skin lesions1228More than 95% of doctors who do this
Removal or shaving of skin growth17More than 70% of doctors who do this
Skin biopsy494More than 95% of doctors who do this

Who their Medicare patients are

661 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 10% · Women 54% · Also on Medicaid 13% · Health risk score 1.10. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 68% · Diabetes 24% · Chronic kidney disease 24% · Coronary heart disease 21% · Cancer 18% · Depression 15% · Atrial fibrillation 13% · COPD 12% · Heart failure 11% · Dementia 5% · Stroke 5%.

The office billed $1,211,250, Medicare allowed $335,768 and paid $248,161; for 4,558 services of 45 kinds; $8,034 of it was for drugs given in the office and $240,127 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20246614,558741.10$1,211,250$248,161
20235743,658721.13$980,991$218,511
20224672,572731.13$675,131$150,249
20212731,320721.28$346,510$80,442
202096290731.75$86,889$19,701

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 22 services

Original Medicare services billed in 2023
Return visit (30+ min)333$53,752$111
Biopsy of related skin growth, first growth207$24,230$95
Destruction of precancer skin growth, 1 growth278$17,202$45
New patient visit (30+ min)174$16,872$97
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm38$14,412$307
Destruction of skin growth, 1-14 growths88$13,116$111
Short return visit (20+ min)110$9,814$77
Destruction of precancer skin growth, 2-14 growths232$9,113$7
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)15$7,790None
Biopsy of related skin growth, each additional growth74$7,059$51
Punch biopsy, first skin growth32$3,931$119
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm23$3,576$138
New patient visit (15+ min)57$3,354$59
Destruction of precancer skin growth, 15 or more growths16$2,837$167
Application of light to destroy precancer skin growth16$2,608$153
Short return visit39$2,286$53
Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm12$1,965$140
Injection into skin growth, 1-7 growths31$1,811$42
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm11$1,465$122
Telehealth originating site facility fee47$1,121$22
Punch biopsy, each additional skin growth11$780$60
Injection, triamcinolone acetonide, not otherwise specified, 10 mg27$51None

2022: 18 services

Original Medicare services billed in 2022
Return visit (30+ min)207$31,107$112
New patient visit (30+ min)217$19,056$88
Biopsy of related skin growth, first growth169$18,512$93
Destruction of precancer skin growth, 1 growth193$10,976$45
Biopsy of related skin growth, each additional growth80$7,093$50
Destruction of skin growth, 1-14 growths56$6,745$114
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm21$6,497$295
Short return visit (20+ min)68$6,192$80
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)12$6,156None
Destruction of precancer skin growth, 2-14 growths162$6,022$7
New patient visit (15+ min)76$4,293$56
Punch biopsy, first skin growth32$3,759$111
Application of light to destroy precancer skin growth12$2,031$156
Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm12$1,457$121
Injection into skin growth, 1-7 growths16$1,039$49
Short return visit16$964$54
Telehealth originating site facility fee41$921$21
Injection, triamcinolone acetonide, not otherwise specified, 10 mg16$25None

2021: 14 services

Original Medicare services billed in 2021
New patient visit (30+ min)148$14,886$101
Return visit (30+ min)93$14,565$121
Biopsy of related skin growth, first growth83$8,922$95
New patient visit (45+ min)45$6,459$144
Destruction of precancer skin growth, 1 growth98$5,806$46
Destruction of precancer skin growth, 2-14 growths81$3,276$7
Destruction of skin growth, 1-14 growths26$3,010$108
Biopsy of related skin growth, each additional growth37$2,981$52
Short return visit (20+ min)25$2,255$87
Punch biopsy, first skin growth17$2,139$126
New patient visit (15+ min)15$1,049$70
Injection into skin growth, 1-7 growths13$817$48
Telehealth originating site facility fee35$773$21
Injection, triamcinolone acetonide, not otherwise specified, 10 mg12$18None

2020: 8 services

Original Medicare services billed in 2020
New patient visit (30+ min)57$5,840$102
Return visit (30+ min)18$1,967$104
Biopsy of related skin growth, first growth17$1,466$77
Destruction of skin growth, 1-14 growths12$1,372$114
New patient visit (15+ min)18$1,313$73
Destruction of precancer skin growth, 1 growth23$1,116$49
Telehealth originating site facility fee32$682$21
Destruction of precancer skin growth, 2-14 growths14$361$6

Medicaid work

$1,411 in 2023

Medicaid paid $1,411 for 25 billed services this clinician did in 2023, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Return visit (30+ min)25$1,411
Medicaid work by year
202325113$1,411
202116115$506
202029116$817
See the largest Medicaid services in earlier years

2021

Largest Medicaid services in 2021
Telehealth originating site facility fee16$506

2020

Largest Medicaid services in 2020
Telehealth originating site facility fee29$817

Drugs they prescribed that Part D paid

$654,576

Pharmacies billed $654,576 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,236) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

1,150 generic and 86 brand-name prescriptions · $654,576 in drug cost · 77 antibiotic prescriptions to 40 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Skyrizi22$471,639$21,438
Dupixent17$61,424$3,613
Clobetasol Propionate89$5,043$57
Fluocinonide122$4,794$39
Fluorouracil50$3,301$66
See all 22 drugs
Every Part D drug this clinician prescribed
Skyrizi22$471,639$21,438
Dupixent17$61,424$3,613
Clobetasol Propionate89$5,043$57
Fluocinonide122$4,794$39
Fluorouracil50$3,301$66
Metronidazole51$2,294$45
Clindamycin Phosphate62$1,892$31
Tacrolimus20$1,847$92
Ketoconazole117$1,682$14
Doxycycline Hyclate56$1,494$27
Ciclopirox37$1,453$39
Tretinoin13$973$75
Triamcinolone Acetonide106$893$8
Betamethasone Dipropionate13$882$68
Nystatin70$818$12
Valacyclovir22$667$30
Hydrocortisone124$521$4
Desonide16$499$31
Mupirocin46$335$7
Minoxidil20$305$15
Cephalexin14$298$21
Hydroxyzine16$109$7

Year by year

Part D prescribing by year
20241,2363670% (0)7%$654,576
20231,1243410% (0)6%$223,371
20227782560% (0)5%$108,868
20213911590% (0)4%$19,308
2020255890% (0)11%$131,966
2019128450% (0)None$23,977

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 22 drugs

Part D drugs prescribed in 2023
Dupixent14$54,249$3,875
Clobetasol Propionate94$8,152$87
Fluocinonide98$5,673$58
Fluorouracil56$4,863$87
Metronidazole38$3,239$85
Ketoconazole103$2,144$21
Clindamycin Phosphate53$2,021$38
Tacrolimus13$1,981$152
Doxycycline Hyclate49$1,794$37
Tretinoin14$1,792$128
Triamcinolone Acetonide143$1,572$11
Ciclopirox41$1,437$35
Betamethasone Diprop Augmented18$1,294$72
Nystatin60$772$13
Mupirocin48$675$14
Lidocaine Hcl Viscous16$660$41
Gabapentin36$522$15
Hydrocortisone88$472$5
Hydroxychloroquine Sulfate13$308$24
Valacyclovir15$283$19
Minoxidil11$214$19
Hydroxyzine14$168$12

2022: 16 drugs

Part D drugs prescribed in 2022
Fluocinonide81$4,880$60
Clobetasol Propionate48$4,830$101
Fluorouracil27$2,478$92
Metronidazole29$2,453$85
Ketoconazole86$1,988$23
Triamcinolone Acetonide110$1,128$10
Doxycycline Hyclate35$986$28
Valacyclovir19$981$52
Ciclopirox36$931$26
Clindamycin Phosphate34$805$24
Nystatin35$783$22
Betamethasone Diprop Augmented12$706$59
Hydrocortisone72$603$8
Mupirocin43$439$10
Hydroxyzine12$311$26
Gabapentin19$238$13

2021: 10 drugs

Part D drugs prescribed in 2021
Fluocinonide46$2,946$64
Clobetasol Propionate28$2,330$83
Fluorouracil20$2,143$107
Ketoconazole34$709$21
Ciclopirox26$680$26
Triamcinolone Acetonide49$601$12
Doxycycline Hyclate16$579$36
Nystatin27$382$14
Mupirocin25$324$13
Hydrocortisone43$282$7

2020: 7 drugs

Part D drugs prescribed in 2020
Clobetasol Propionate12$1,098$92
Fluocinonide14$672$48
Triamcinolone Acetonide29$670$23
Doxycycline Hyclate14$628$45
Ketoconazole31$452$15
Hydrocortisone21$121$6
Prednisone11$80$7

2019: 3 drugs

Part D drugs prescribed in 2019
Triamcinolone Acetonide14$307$22
Mupirocin15$209$14
Prednisone11$147$13

Money from drug and device companies

$28 in 2025

Industry payments by year
202511None$28
202322None$38
201922None$128

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
STRATA Skin SciencesXtrac$28
1 payment
  • Meals for Xtrac · 2025-11-17 · $28
See the published payment
Every published payment
STRATA Skin SciencesMeals · 2025-11-17Xtrac$28
See earlier years (2023, 2019)

2023: $38

Payments by company in 2023
Galderma Laboratories L.P.None$23
1 payment
  • Meals · 2023-03-28 · $23
PfizerCibinqo$15
1 payment
  • Education for Cibinqo · 2023-04-12 · $15

2019: $128

Payments by company in 2019
AllerganNone$97
1 payment
  • Meals · 2019-03-02 · $97
AmgenEnbrel$30
1 payment
  • Meals for Enbrel · 2019-09-12 · $30

Professional record

NPI
1295197028
Licence
CA A151279California A151279: Current · expires 2027-04-30
Trained
Stanford University School of Medicine, 2016
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2016-03-22
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128